Inovio pharmaceuticals stock.

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2023. Find the latest Inovio Pharmaceuticals ...

Inovio pharmaceuticals stock. Things To Know About Inovio pharmaceuticals stock.

Inovio Pharmaceuticals is an American biotechnology company focused on the discovery, development, ... Inovio in August 2020, claiming it exaggerated evidence of its coronavirus vaccine's efficacy in order to boost its stock price. License of electroporation deviceNov 9, 2021 · FDA Lifts Partial Clinical Hold on INNOVATE Phase 3 Segment INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced that the U.S. Food and Drug Administration (FDA) provided authorization to proceed for INOVIO's INNOVATE Phase 3 ... The stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large fall of 17% over the last month ... Inovio (INO) delivered earnings and revenue surprises of -14.29% and 42.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?Nov 30, 2023 · Inovio Pharmaceuticals Stock Forecast. ... According to 1 stock analyst, the 12-month stock price forecast for INO stock stock is $2.00, which predicts an increase of ...

Find the latest Inovio Pharmaceuticals, Inc. (INO) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

Inovio Pharmaceuticals Inc. closed $1.59 below its 52-week high ($1.99), which the company reached on January 13th. The stock outperformed some of its competitors …Inovio (INO) delivered earnings and revenue surprises of -14.29% and 42.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

plymouth meeting, pa., june 23, 2023 (globe newswire) - inovio (nasdaq:ino) has released the following pursuant to an order of the united states district court eastern district of pennsylvania: united states district court eastern district of pennsylvania in re inovio pharmaceuticals, inc. derivative litigation lead case no. 2:20-cv-01962-gjp notice of …INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2023. Find the latest Inovio Pharmaceuticals ...Stock split history for Inovio Pharmaceuticals since 1998. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.Let's consider two such stocks: Inovio Pharmaceuticals ( INO -2.10%) and Cronos Group ( CRON). INO data by YCharts. 1. Inovio Pharmaceuticals. Inovio Pharmaceuticals is a clinical-stage biotech ...In a major shakeup at Inovio Pharmaceuticals, company co-founder J. Joseph Kim is out as CEO. ... In early morning trading, Inovio's stock was down more than 31% at $1.72 per share.

Inovio Pharmaceuticals (INO 4.20%) ... This leads to the biggest concern of all about Inovio. The biotech stock has skyrocketed in 2020 based on expectations of success for its COVID-19 vaccine ...

Galectin Therapeutics Inc. 1.99. -0.13. -6.13%. Get Inovio Pharmaceuticals Inc (INO:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

As of June 30, 2022, Inovio had 247.5 million shares of common stock outstanding and 267.8 million shares of common stock outstanding on a fully diluted basis. Total operating expenses were $104.9M.Shares Outstanding: As of September 30, 2023, INOVIO had 269.7 million common shares outstanding and 290.6 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible …Get Inovio Pharmaceuticals Inc (INO.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsInovio Pharmaceuticals (INO) Company Description: Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA ...Inovio Pharmaceuticals, Inc. Common Stock (INO) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time Key Data Bid Price and Ask Price The bid & ask refers to the price that an... Nov 30, 2023 · Inovio Pharmaceuticals Inc INO Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation... Mar 1, 2023 · The year-over-year increase in G&A expenses was primarily due to a $14.0 million non-cash expense related to the settlement of INOVIO's securities class action litigation, including the issuance of INOVIO common stock as part of the settlement, $14.3 million in higher legal expenses, primarily related to litigation matters, $6.9 million in one ...

These factors combined to bring our net loss for the second quarter of 2023 to $35.5 million or $0.13 per share basic and dilutive, compared to a net loss of $108.5 million or $0.46 per share ... Shares of Inovio Pharmaceuticals ... Inovio's stock went on a tear during the first half of the year -- gaining as much as 860% -- mostly thanks to its efforts to develop a vaccine for COVID-19.Inovio (INO) delivered earnings and revenue surprises of -14.29% and 42.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?Find real-time INO - Inovio Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. ... Inovio Pharmaceuticals Inc (NASDAQ:INO) 0.4291. Delayed Data. As of Nov 17 ...If You Invested $1,000 in Inovio Pharmaceuticals’s IPO, This Is How Much Money You'd Have Now. ... Right now, though, the stock looks like a risky coronavirus play at best.

If you are thinking of buying or selling Inovio Pharmaceuticals stock, you should check out this FREE detailed report on its balance sheet.. A Different Perspective. While the broader market lost ...As of December 31, 2022, INOVIO had 253.1 million common shares outstanding and 271.0 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt.

The consensus among analysts is that Inovio Pharmaceuticals Inc (INO) is a Hold stock at the moment, with a recommendation rating of 3.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 3 have rated it as a Hold, with 0 advising it as a Buy. 0 have rated the stock as Underweight.Stock analysis for Inovio Pharmaceuticals Inc (INO:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Nov 30, 2023 · Inovio Pharmaceuticals Inc INO Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation... Background Additional SARS-CoV-2 vaccines that are safe and effective as primary vaccines and boosters remain urgently needed to combat the COVID-19 pandemic. We describe the safety and durability of the immune responses following two primary doses and a homologous booster dose of an investigational DNA vaccine (INO-4800) targeting …WebFind the latest Inovio Pharmaceuticals, Inc. (INO) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Get Inovio Pharmaceuticals Inc (INO.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.

Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.Web

INOVIO Pharmaceuticals Stock History June 1, 2020, started by offering investors new options as they wait for the July 10, 2020 expiration date. The INO stocks have been going up since March 2020.

After market hours on Tuesday, Inovio revealed that it booked revenue of $839,000 in its fourth quarter of 2021, well down from the $5.6 million in the same quarter the previous year. The net loss ...Nov 29, 2023 · 1 Wall Street analysts have issued twelve-month target prices for Inovio Pharmaceuticals' stock. Their INO share price targets range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 423.3% from the stock's current price. Dec 21, 2021 · The Food and Drug Administration reversed a decision that barred Inovio Pharmaceuticals from testing its ... Inovio stock hit a high mark of 33.79 in June 2020 after the biotech company received a ... Lead Case No. 2:20-cv-01962-GJP. NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER. DERIVATIVE ACTIONS. TO: ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF INOVIO PHARMACEUTICALS, INC ...WebInovio Pharmaceuticals reported quarterly losses of 15 cents per share which beat the analyst consensus estimate of a loss of 30 cents. The company also reported quarterly sales of $9.15 million ...Nov 30, 2023 · Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA ... Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.WebJan 29, 2022 · Let's consider two such stocks: Inovio Pharmaceuticals ( INO -2.10%) and Cronos Group ( CRON). INO data by YCharts. 1. Inovio Pharmaceuticals. Inovio Pharmaceuticals is a clinical-stage biotech ... Jacqueline Shea, Ph.D. Dr. Jacqueline Shea has served as INOVIO’s President and Chief Executive Officer (CEO) since May 2022. She is responsible for establishing and leading INOVIO’s overall corporate strategy across its clinical programs and advancing its DNA medicines platform. Dr. Shea joined the Company in March 2019 as Chief Operating ...

Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.WebInovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its ... Biotechnology firm Inovio Pharmaceuticals (INO) was one of the first companies to enter the race to release a Covid-19 vaccine, but delays have set back the process and it remains in the development stage. The company’s share price fell in late 2020, but it has gained 19 per cent so far this year, with the firm moving ahead with …Instagram:https://instagram. best financial advisors new yorkbest stock market websiteadvisor centerdental insurance plans for veterans The Food and Drug Administration reversed a decision that barred Inovio Pharmaceuticals from testing its ... Inovio stock hit a high mark of 33.79 in June 2020 after the biotech company received a ... personal branding traininggood brokers for forex Inovio Pharmaceuticals ( INO) reported Q3 2023 earnings per share (EPS) of -$0.13, meeting estimates of -$0.13 by 0.29%. In the same quarter last year, Inovio Pharmaceuticals 's earnings per share (EPS) was -$0.15. Inovio Pharmaceuticals is expected to release next earnings on 02/28/2024, with an earnings per share (EPS) …Web celz stocktwits Pennsylvania-based Inovio Pharmaceuticals is a biotechnology business with a focus on DNA-based medicine. During the onset of the COVID-19 crisis, some traders bought INO stock as a bet on Inovio ...Inovio Pharmaceuticals reported quarterly losses of 15 cents per share which beat the analyst consensus estimate of a loss of 30 cents. The company also reported quarterly sales of $9.15 million ...